HOME >> BIOLOGY >> NEWS
'Trap' crop saves Texas cross timbers melon production

STEPHENVILLE -- Mark Allison, Comanche County farmer, first noticed a few yellow vines in his watermelon crop in the late 1990s but didn't think much of it.

There are a number of diseases that cause melon vines to yellow, but this one thumbed its nose at conventional treatments. The next year, it struck again, turning half his crop into a mass of yellow, wilted heap of vines, leaves and unmarketable fruit.

At war with diseases, often besieged by unpredictable weather, melon farming is a high-investment, high-risk crop. With tens of thousands of dollars in production costs at stake, Allison called his first line of defense, Bob Whitney, Texas Cooperative Extension agent for Comanche County.

Whitney brought in Dr. Forrest Mitchell, a Texas Agricultural Experiment Station entomologist. Mitchell, who is based at the Texas A&M University System Agricultural Research and Extension Center at Stephenville, got right to work. Mitchell had been involved in the hunt for the cause of yellow vine disease since the mid 1990s.

In 1991, yellow vine disease made its premier performance in Texas and Oklahoma, striking melon and cantaloupe fields with a vengeance. Some fields were completely wiped out. By the mid-1990s, it was clear the melon industry throughout the region was at risk.

In response to the threat, Mitchell joined a multi-disciplinary task force that included Texas A&M System scientists, U.S. Department of Agriculture scientists at Lane, Okla., and Oklahoma State University researchers. Work proceeded on various fronts, as some theories about the disease were proven and others discarded.

For example, in 1997, Mitchell and his colleagues at the Stephenville center were the first to positively identify a rod-shaped cell bacterium-like organism that was at work in yellow vine disease.

The scientists knew an insect had to be spreading the disease, but which one remained a mystery for some time. At first the chief suspect wa
'"/>

Contact: Robert Burns
903-834-6191
Texas A&M University - Agricultural Communications
7-Jul-2004


Page: 1 2 3 4

Related biology news :

1. Disease-resistant papaya saves Hawaiian papaya industry
2. Salmonella infects cells and saves itself by altering host membrane lipids
3. Busy sequencing technique saves money and time
4. Common asthma drug saves patients money, trips to hospital
5. Dead zone area shrinking, Texas A&M prof says
6. Hardy buoys: Texas A&M project predicts oil spill movements
7. Water on Mars not easy to find, says Texas A&M researcher
8. Weed from hell found in Texas
9. Global competition closes Texas sawmills/paper mills
10. Fire ant killing protozoa found in 120 Texas counties
11. Tiny beetle wreaks havoc on Texas ornamental tree nurseries

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Trap crop saves Texas cross timbers melon production

(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
Cached News: